The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

By I. Ben-Sahra, K. Laurent, A. Loubat, S. Giorgetti-Peraldi, P. Colosetti, P. Auberger, J. Tanti, Y. Marchand-Brustel, F. Bost. Oncogene, 2008

880 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/b8b3377d94403d93394fd698bdf01da5d719646c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Funda Meric-Bernstam
2. I. Ben-Sahra

In Oncology

1. M. Hung
2. G. Hortobagyi

Citations in the corpus

• Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. (2011, methodology): “3 INTRODUCTION Metformin a widely used anti-diabetic drug appears to reduce the incidence of cancer in diabetic patients (1), and to inhibit cancer cell proliferation and tumor growth in animal models (2-4).”
• Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. (2009, background): “In addition, metformin has been shown to inhibit the growth of cancer cells, including breast cancer, in vitro(19-22) and of tumors in vivo.(21-24) We hypothesized that the antiproliferative effects of metformin might increase the effectiveness of neoadjuvant chemotherapy in diabetic patients with b”